BioMarin (BMRN) Pharmaceutical announced new data from 14 studies were presented at the American Society for Bone and Mineral Research 2025, ASBMR, Annual Meeting in Seattle, including results demonstrating treatment with VOXZOGO led to anatomical improvements in spinal morphology in young children, and continued efficacy in children who received the medicine after the onset of puberty. Researchers found that children who received VOXZOGO for 52 weeks experienced measurable improvement in interpedicular distance and greater spinal canal width in all five vertebrae in the lower back compared to children who received placebo. Children who received VOXZOGO in this study also demonstrated a reduction in thoracolumbar kyphosis, or excessive curvature of the spine, compared to those who received placebo.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- BioMarin Pharmaceutical: Promising Growth with Palynziq Expansion and Robust Product Pipeline
- BioMarin Pharmaceutical’s Growth Potential: Promising Phase 3 Data, Revenue Growth, and Strategic Initiatives Support Buy Rating
- BioMarin initiated with a Neutral at H.C. Wainwright
- BioMarin announces Phase 3 data for PALYNZIQ
- BioMarin initiated with an Outperform at Raymond James